# Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma

> **NCT07469735** · NA · NOT_YET_RECRUITING · sponsor: **Huashan Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Glioma
- Diffuse Glioma
- Recurrent Gliomas

## Interventions

- **DRUG:** Oral Vorasidenib administered once daily for up to 12 treatment cycles (28 days per cycle) as IDH-targeted therapy in participants with recurrent or residual IDH-mutant diffuse glioma.

## Key facts

- **NCT ID:** NCT07469735
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07469735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07469735, "Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07469735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*